# IBI3014 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors

Source: https://onco.cc/trials/nct06974812/  
OnCo record `nct06974812` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of IBI3014 in advanced solid tumours, run by Innovent Biologics (Suzhou) Co. Ltd., now recruiting.

## Summary

IBI3014 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors. ClinicalTrials.gov record last updated 2026-01-29: recruiting. Enrollment is planned at 250 participants. Primary completion is estimated at 2026-06-30. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications. Registered interventions: IBI3014, IBI3014, IBI3014, IBI3014, IBI3014, IBI3014, IBI3014, IBI3014. Registered primary measures: The Safety profile of patients in Phase 1 dose escalation part、Phase 1 dose expansion and Phase 2 dose optimization; Dose limiting toxicity (DLT) of IBI3014 in Phase 1 dose escalation; ORR per RECIST v1.1 in Phase 1 dose expansion and Phase 2 dose optimization.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-10-06
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06974812
- Phase: 1/2
- Setting: IBI3014 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors
- Sponsor: Innovent Biologics (Suzhou) Co. Ltd.
- Enrolled: 250

## Notes

- ClinicalTrials.gov record last updated 2026-01-29: recruiting. Enrollment is planned at 250 participants. Primary completion is estimated at 2026-06-30. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications.

## Sources

- ClinicalTrials.gov NCT06974812: https://clinicaltrials.gov/study/NCT06974812

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- targets: [TROP2](https://onco.cc/targets/trop2/)
- companies: [Innovent Biologics](https://onco.cc/companies/innovent/)
- drugs: [IBI3014](https://onco.cc/drugs/ibi3014/)

---
JSON: https://onco.cc/api/v1/entities/nct06974812.json